Cel-Sci (CVM) director Baillavoine received 110,000 Options
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Bruno Jean-Marie Baillavoine (director at Cel-Sci Corporation, CVM) reported that they received 110,000 Options on Aug 14, 2026.
- Reporting person
- Baillavoine Bruno Jean-Marie
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Grant or award (A) | OptionsOn 110,000 Common Stock1 | +110,000 | $0.01 | $1,100 | 138,021 direct |
Holdings before and after
- Options: 28,021 to 138,021 direct
Footnotes from the filing
- 1. The stock options vest in three (3) equal annual installments commencing one year after the grant date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Baillavoine report in this CVM Form 4?
Bruno Jean-Marie Baillavoine (director at Cel-Sci Corporation, CVM) reported that they received 110,000 Options on Aug 14, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for CVM
Across the 15 sessions after earlier CVM headlines, the stock closed higher 8 times and lower 6 times, with a median move of 8.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CVM | SPY |
|---|---|---|---|
| Aug 17, 2026 | CEL-SCI Reports Fiscal Third Quarter 2026 Results | +0.6% | -0.5% |
| Aug 4, 2026 | CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study | +8.8% | +1.8% |
| Jul 30, 2026 | Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | +7.0% | +1.7% |
| Jul 13, 2026 | CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer | -11.6% | -0.8% |
| Jun 24, 2026 | CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care | -2.5% | -0.0% |
| Jun 17, 2026 | CEL-SCI Announces Closing of Offering | +8.9% | -1.2% |
Earlier insider filings at CVM
- Aug 17, 2026SEC Form 4 filed by Senior Vice President Cipriano John
- Aug 17, 2026SEC Form 4 filed by Chief Scientific Officer Talor Eyal
- Aug 17, 2026SEC Form 4 filed by Chief Financial Officer Prichep Patricia B
- Aug 17, 2026SEC Form 4 filed by Chief Executive Officer Kersten Geert R
- Jul 1, 2026Chief Scientific Officer Talor Eyal was granted 2,307 shares, increasing direct ownership by 33% to 9,318 units (SEC Form 4)
Keep researching CVM
- CVM insider tradesEvery buy and sale reported by Cel-Sci Corporation officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- CVM financial statementsRevenue, profit, cash flow and balance sheet from Cel-Sci Corporation's SEC filings.
Quantisnow market dataAMEX
CVM
Cel-Sci Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1997
Get push alerts for CVM
Full CVM profile on Quantisnow Follow CVM and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time